Bard PowerPort Lawsuit
(Implanted Port Catheter)
Updated November 2, 2026. MDL-3081, before Judge David G. Campbell in the District of Arizona, covers Bard PowerPort implanted port catheters that plaintiffs allege fracture, migrate, and cause bloodstream infections and blood clots. 4,345 cases are pending (4,636 total), growing about 190 a month. The first bellwether ended in a defense verdict with a hung jury on design defect. The second, Divelbliss, the first catheter-fracture case to reach a jury, returned a $40 million plaintiff verdict on September 4, 2026, the first plaintiff verdict in the MDL. The third, Lattanzio, also an infection case, ended in a defense verdict for Bard, Law.com reported on October 30, 2026. The fourth, Hicks, a thrombosis case, is set for trial on December 1, 2026. There is still no settlement.
Key Takeaways
- 4,345 cases pending as of November 2026, growing about 190 a month, one of the fastest-growing device MDLs of its size
- The first bellwether (Cook, an infection case) ended in May 2026 in a defense verdict on the decided claims, with a hung jury on design defect; no ruling on plaintiff's post-trial motion had been reported as of early November 2026
- Divelbliss, the first fracture case to reach a jury, returned a $40 million plaintiff verdict on September 4, 2026; the third bellwether, Lattanzio (infection), ended in a defense verdict, Law.com reported on October 30, 2026
- Next is Hicks, a thrombosis case, set for trial December 1, 2026; the court denied Bard's summary-judgment motion on October 26, 2026
- Fracture claims are only about 12% of the inventory; infection and thrombosis claims dominate the docket
- The first plaintiff verdict came in Divelbliss ($40 million, September 4, 2026); there is still no settlement, and we do not publish projected per-case values
November 2026 Updates Latest
The fourth bellwether, Hicks v. Becton, Dickinson, is set for trial from December 1 to 21, 2026 under First Amended CMO 50. It is a thrombosis case. According to the court's October 26, 2026 order denying Bard's motion for summary judgment, the Missouri plaintiff received a Bard X-Port with a ChronoFlex polyurethane catheter on February 21, 2021 for breast-cancer chemotherapy; the device was occluded with thrombus during some infusions and was surgically removed on August 3, 2022. Claims for design defect, failure to warn, concealment, and punitive damages remain for trial under Missouri law, and the court held that Bard had not shown, as a matter of undisputed fact, that the X-Port qualifies for the "unavoidably unsafe product" defense to strict liability. Judge Jennifer Choe-Groves of the U.S. Court of International Trade, sitting by designation, will preside. It will be the first thrombosis bellwether, following Cook (infection; defense verdict on the decided claims, hung jury on design defect), Divelbliss (fracture; $40 million plaintiff verdict) and Lattanzio (infection; a defense verdict, Law.com reported on October 30). Separately, the court has directed the parties to submit a joint proposal on settlement procedures by November 6, with a conference on November 13. 4,345 cases are pending (4,636 total). Follow the bellwether tracker.
Lattanzio: defense verdict for Bard in the third bellwether (reported Oct 30, 2026)
Law.com reported on October 30, 2026 that the jury in Lattanzio, the third bellwether and the second infection case to be tried, returned a defense verdict for Bard. The claim-by-claim findings have not been made public. The Florida plaintiff's PowerPort had a silicone catheter, and the court's September 25 summary-judgment ruling had left design defect, failure to warn, misrepresentation or concealment, and punitive damages for the jury. After three trials, the two infection cases (Cook and Lattanzio) have gone to the defense on the decided claims, and the one fracture case (Divelbliss) produced a $40 million plaintiff verdict.
Judgment entered on the Divelbliss verdict (Sep 10); Bard seeks a new trial (Oct 8, 2026)
On September 10, 2026 the court entered judgment for the plaintiff in Divelbliss: $40 million, plus post-judgment interest at 4.15% and costs. Bard moved for a new trial on October 8, 2026, arguing that the award was excessive, as reported by HarrisMartin. No ruling on that motion has been reported.
Summary judgment denied in Lattanzio, the third bellwether (Sep 25, 2026)
On September 25, 2026 the court denied Bard's motion for summary judgment in Lattanzio, the third bellwether. The Florida plaintiff's PowerPort, which had a silicone catheter, was implanted on August 16, 2013; the plaintiff developed a staph bloodstream infection and possible sepsis, and the port was removed on December 13, 2013. Claims for design defect, failure to warn, misrepresentation or concealment, and punitive damages went forward to trial. According to Bloomberg Law, the court also rejected Bard's argument that the claims were time-barred. The final pretrial conference was held September 15, and the trial window ran from October 13 to 30.
Court limits two defense experts across the MDL (Sep 8, 2026)
On September 8, 2026 the court issued two MDL-wide rulings limiting defense experts. Dr. Sydnor may not offer design-defect opinions. Christy Foreman may not offer infection-rate opinions and may not tell jurors that FDA "approved" the labeling through the 510(k) process. The rulings apply across the MDL, not just to one case.
Divelbliss verdict: $40 million for the plaintiff (Sep 4, 2026)
On September 4, 2026, the Divelbliss jury returned a $40 million compensatory verdict for the plaintiff, finding design defect and failure to warn and declining punitive damages. It is the first plaintiff verdict in the MDL and the first catheter-fracture case decided by a jury. The case involved a subclavian placement with a Bard silicone Groshong catheter. Read our full write-up of the verdict.
Summary-judgment win, and a post-trial motion in Cook
Heading into trial, Judge Campbell had denied nearly all of Bard's summary judgment motion on March 5, a major plaintiff win. Plaintiff's counsel has since moved for a new trial or judgment as a matter of law in Cook, arguing faulty jury instructions and that the jury was pressured by a court-ordered deadline; that motion was fully briefed in July, and no ruling on it had been reported as of early November 2026.
Bellwether slate cut from six cases to five
The bellwether slate was cut from six cases to five. In CMO 48, issued May 19, 2026, Judge Campbell declined to substitute an alternate after second bellwether plaintiff Wanda Miller died in February 2026 and her family chose not to continue. His stated reasoning is useful intelligence on the inventory: fracture claims represent only about 12% of the cases in this MDL, so two of six fracture bellwethers would have over-weighted that injury category. Infection and thrombosis claims dominate the docket. The five bellwethers span three catheter materials: Chronoflex polyurethane, silicone Groshong, and silicone. Three have now been tried (Cook, Divelbliss and Lattanzio). The two still to be tried are set by case management order: Hicks for December 1 to 21, 2026 (First Amended CMO 50) and Sorensen for February 2 to 19, 2027 (CMO 42).
No global settlement; court orders a settlement-procedures proposal by Nov 6
There is no global settlement and no settlement fund in port catheter litigation as of November 2026, though Divelbliss produced the first plaintiff verdict ($40 million) on September 4. We do not publish projected per-case figures, because no verified source has published any. In a September 3, 2026 minute entry, the court directed the parties to submit a joint proposal on settlement procedures for the MDL by November 6, 2026, and set a November 13 conference to discuss it, pointing them to the order that set the settlement process in Bard's IVC filter MDL (MDL-2641). That is a procedural order, not an announced settlement. Judge Campbell set out the fallback in CMO 48: cases not resolved by settlement after the bellwethers "will be transferred or remanded to their home districts for resolution."
Key Facts (November 2026)
| Pending Actions | 4,345 cases in federal MDL (November 2026) |
| Growth Rate | 1,000+ new cases in 2025 alone |
| Defendants | C.R. Bard, Bard Access Systems, Becton Dickinson (parent) |
| Presiding Judge | Hon. David G. Campbell (D. Arizona) |
| MDL Created | August 8, 2023 |
| FDA Adverse Events | 5,333+ reports in MAUDE database |
| Catheter Fracture Rate | 1.1% - 5.0% per medical literature |
| First Bellwether (Cook) | Tried Apr-May 2026: defense verdict on decided claims, hung jury on design defect |
| Second Bellwether (Divelbliss) | Sept 4, 2026: $40M plaintiff verdict (first fracture case to a jury); judgment entered Sept 10 |
| Third Bellwether (Lattanzio) | Infection case tried Oct 2026: defense verdict, per Law.com (Oct 30, 2026) |
| Next Trial | Hicks (thrombosis), Dec. 1, 2026, Judge Jennifer Choe-Groves presiding; summary judgment denied Oct. 26 |
| Fracture Share of Docket | About 12% per CMO 48; infection and thrombosis dominate |
| New Jersey MCL | Bergen County, Judge Gregg Padovano (designated Oct 15, 2024) |
| Settlement Status | No settlement or fund; court ordered a joint proposal on settlement procedures by Nov. 6, 2026 |
| Can You Still File? | Yes, cases are actively being filed |
Explosive Case Growth
One of the fastest-growing medical device MDLs. Case count has surged 388% since January 2025 as cancer patients report catheter fractures and complications.
Source: JPML MDL Statistics Reports, January 2025-November 2026
Peer-Reviewed Research Finding (2016)
A study from BAM Federal Institute for Materials Research found that loss of barium sulfate filler particles near the catheter surface creates "predetermined sites of fracture"—microscopic notches that make the catheter vulnerable to breaking.
Source: Braun et al. (2016), Journal of the Mechanical Behavior of Biomedical Materials, PMID: 27552159
1 What Is This Lawsuit About?
The Bard PowerPort is an implanted port catheter—a medical device surgically placed under the skin to provide long-term vascular access for chemotherapy, IV medications, and blood draws. The device consists of a port (reservoir) placed in the chest and a catheter tube that runs into a large vein near the heart.
Plaintiffs allege that Bard's PowerPort devices are defectively designed. The catheters use a polyurethane material called "Chronoflex" containing barium sulfate (to make the device visible on X-rays). Over time, the barium sulfate particles separate from the catheter surface, weakening the material and creating sites prone to fracture.
When these catheters fracture, fragments can migrate through the bloodstream to the heart or lungs, requiring emergency surgery to remove. The lawsuits also allege the surface degradation makes the catheters more susceptible to bacterial colonization, leading to serious bloodstream infections.
These devices reached the market through the FDA's 510(k) pathway, which clears a device if it is substantially equivalent to one already on sale, without the clinical trials required for higher-risk approvals. Plaintiffs argue that pathway allowed design problems to persist without the scrutiny a genuinely new device would face. Bard has cleared more than a dozen PowerPort variants this way since 2006.
The corporate history matters for who is on the hook. C.R. Bard designed and sold the PowerPort line, and Becton, Dickinson and Company acquired Bard in December 2017 and is named as the parent. Both are defendants in the MDL, which is why the first bellwether is captioned Cook v. Becton, Dickinson.
2 Bellwether Trial Tracker
MDL-3081 is being worked out through a five-case bellwether program before Judge David G. Campbell. The outcomes of these trials, not a global settlement, are what will set the value of the litigation. This tracker is updated after each verdict. As of November 2026 three bellwethers have been tried, and the fourth, Hicks, is set to begin December 1, 2026.
| Trial | Case | Injury | Catheter material | Date | Outcome |
|---|---|---|---|---|---|
| Trial 1 | Cook v. Becton, Dickinson | Infection | Not publicly specified | Apr 21 – early May 2026 | Defense verdict on failure to warn, failure to instruct and consumer fraud; hung jury on design defect. No ruling on plaintiff’s post-trial motion for a new trial or judgment as a matter of law had been reported as of early November 2026. |
| Trial 2 | Divelbliss v. Becton, Dickinson | Fracture (first to a jury) | Silicone Groshong (subclavian) | Aug 18 to Sep 4, 2026 | Unanimous plaintiff verdict, September 4, 2026: $40 million in compensatory damages, no punitive damages. Jury found strict and negligent design defect and failure to warn; found no manufacturing defect and no fraudulent concealment. Judgment entered Sept 10, 2026. First plaintiff verdict in the MDL and the first fracture case decided by a jury. Bard moved for a new trial on Oct 8, 2026, as reported by HarrisMartin; no ruling has been reported. |
| Trial 3 | Lattanzio v. Becton, Dickinson (No. 24-cv-00680) | Infection (bloodstream infection/possible sepsis) | Silicone | Oct 13 to Oct 30, 2026 (trial window, CMO 42) | Defense verdict for Bard, Law.com reported on Oct 30, 2026. Claim-by-claim findings were not available in any public source we could read. Summary judgment had been denied Sept 25, 2026. |
| Trial 4 | Hicks v. Becton, Dickinson (No. 23-cv-01703) | Thrombosis | ChronoFlex polyurethane (Bard X-Port) | Dec 1 to Dec 21, 2026 (First Am. CMO 50) | Not yet tried. Summary judgment denied Oct 26, 2026; design defect, failure to warn, concealment and punitive damages claims remain under Missouri law. Judge Jennifer Choe-Groves will preside. |
| Trial 5 | Sorensen v. Becton, Dickinson (No. 23-cv-02557) | Not publicly confirmed | Not publicly confirmed | Feb 2 to Feb 19, 2027 (CMO 42) | Not yet tried. |
Trials 1 to 3 have been tried; the Lattanzio defense verdict is as reported by Law.com on October 30, 2026, and its claim-by-claim findings have not been made public. The remaining two trial windows are set by case management order: Hicks (December 1 to 21, 2026) under First Amended CMO 50, and Sorensen (February 2 to 19, 2027) under CMO 42. Judge Jennifer Choe-Groves of the U.S. Court of International Trade, sitting by designation, will conduct the Hicks trial. Lattanzio's injury and catheter material are drawn from the court's September 25, 2026 summary-judgment ruling, and Hicks's from its October 26, 2026 summary-judgment ruling; the injury type and catheter material for Sorensen are not confirmed in any source we can verify, so they are left unstated. Under CMO 48, cases not resolved after the bellwethers are to be transferred or remanded to their home districts.
3 The First Bellwether: Cook
The first bellwether, Cook v. Becton, Dickinson, was an infection case, and it set the tone for how these claims may play out. Robert Cook, a Minnesota colorectal-cancer patient, was hospitalized for six days and had chemotherapy delayed about two weeks after his PowerPort became infected. In opening statements on April 21, 2026, plaintiff's counsel told jurors that Bard had known for decades that its devices were prone to infection yet shelved safer technologies, including antimicrobial coatings and smoother catheter materials, developed as early as 2005. Cook's expert, interventional radiologist Dr. Darren Hurst, testified that his hospital abandoned Bard products in 2014.
Heading into trial, Judge Campbell had denied nearly all of Bard's summary-judgment motion on March 5, 2026, which was a significant plaintiff win. In early May 2026 the jury returned a defense verdict on the claims it decided, clearing Bard and Becton Dickinson on failure to warn, failure to instruct, and consumer fraud, and hung on the central design-defect claim, leaving it unresolved. Plaintiff has since moved for a new trial or judgment as a matter of law, arguing faulty jury instructions and that the jury was pressured by a court-ordered deadline. The motion was filed June 3, 2026 and fully briefed on July 15, and no ruling on it had been reported as of early November 2026. The first plaintiff verdict in the litigation came later, in the second bellwether, Divelbliss, on September 4, 2026 ($40 million).
The early read is narrow but useful for intake: an infection theory may be harder for plaintiffs than a fracture or migration theory. Divelbliss, a fracture case, tested that and produced the first plaintiff verdict. The third trial, Lattanzio, returned to an infection claim and also ended in a defense verdict, Law.com reported on October 30, 2026.
4 Why the Slate Went From Six to Five
The bellwether slate was cut from six cases to five. In CMO 48, issued May 19, 2026, Judge Campbell declined to substitute an alternate after the second bellwether plaintiff, Wanda Miller, died in February 2026 and her family chose not to continue.
His reasoning is worth reading if you are evaluating inventory. Fracture claims represent only about 12% of the cases in this MDL, so keeping two of six fracture bellwethers would have over-weighted that injury relative to the docket. He also set out the fallback for cases that do not resolve: under CMO 48, cases not resolved by settlement after the bellwethers are to be transferred or remanded to their home districts for resolution. That backstop matters, because it means a claimant's own home district may ultimately try the case rather than the MDL court in Arizona.
5 The Injury Mix: Fracture Is Not the Common Claim
This is one of the most useful facts for a firm weighing whether to take these cases, and almost no competitor page states it. Fracture is the headline injury, but it is not the common one. Per Judge Campbell in CMO 48, fracture claims are only about 12% of the MDL. Infection and thrombosis claims make up the large majority of the inventory.
That distribution shapes the bellwether program, the order in which the injuries are tested at trial, and the kind of case that is most numerous in the docket. An intake process built only around dramatic catheter-fracture-and-migration stories will misjudge what most of the actual claims look like. The first three bellwethers illustrate the split directly: Cook was an infection case that ended in a defense verdict, Divelbliss was the first fracture case and produced the first plaintiff verdict, and Lattanzio, a second infection case, ended in a defense verdict, Law.com reported. The fourth, Hicks, set for December 2026, will be the first thrombosis case tried.
6 The Three Catheter Materials
The five bellwethers deliberately span three catheter materials, because the design-defect theory is not identical across them. The materials are Chronoflex polyurethane, the silicone Groshong catheter, and silicone. Divelbliss, tried in August and September 2026, involved a silicone Groshong catheter placed in the subclavian vein. Lattanzio, tried in October 2026, involved a PowerPort with a silicone catheter. Hicks, set for trial in December 2026, involves a Bard X-Port with a ChronoFlex polyurethane catheter, according to the court's October 26, 2026 summary-judgment order.
Testing more than one material is how the program probes whether the alleged defect is specific to the barium-sulfate-loaded polyurethane or extends to the silicone lines as well. For a claimant, the material of the specific device implanted can matter, and it is recorded in the surgical and device records rather than something a patient would usually know from memory.
7 The Alleged Defect Mechanism: Barium Sulfate & Chronoflex
The core allegation is about the catheter's material composition and how it is said to degrade over time. Plaintiffs allege that barium sulfate, added to make the catheter visible on X-rays, leaches out of the polyurethane and leaves the surface pocked with fissures, pits, and cracks that concentrate stress and become fracture initiation points. The same surface damage is alleged to make the catheter more hospitable to bacterial colonization. These are allegations the plaintiffs must prove at trial:
Material Composition
- Chronoflex AL — Polyurethane polymer used in the catheter
- Barium Sulfate — Radiopacifying agent added to make catheter visible on X-rays
Degradation Process
- Barium sulfate particles separate from the polyurethane over time
- Particle loss creates microscopic notches/pitting on catheter surface
- These notches act as stress concentrators and fracture initiation points
- Surface damage also increases bacterial colonization risk
8 Reported Complications & Injuries
The FDA MAUDE database contains over 5,333 adverse event reports for Bard PowerPort devices. Reported complications include:
Catheter Fracture & Migration
- Catheter breaks into fragments inside the body
- Fragments migrate to heart or pulmonary arteries
- Incidence rate: 1.1% - 5.0% per medical literature
- Requires emergency surgical retrieval
Bloodstream Infections
- Catheter-related bloodstream infections (CRBSI)
- Sepsis (life-threatening systemic infection)
- Per CDC: CLABSIs cause thousands of deaths yearly
- Especially dangerous for immunocompromised cancer patients
Blood Clots (Thrombosis)
- Deep vein thrombosis (DVT)
- Pulmonary embolism risk from migrating clots
- Port occlusion requiring intervention
Other Complications
- Pinch-off syndrome (catheter compression)
- Cardiac arrhythmias from migrated fragments
- Unplanned surgical removal
- Death (in severe cases)
9 FDA Regulatory History
FDA clears PowerPort Implanted Titanium Port via 510(k) pathway (K060812). Class II device; no clinical trials required.
Multiple PowerPort variants cleared including MRI-compatible, Groshong catheter, ClearVUE Slim, and ECG-enabled versions.
FDA documents 25 recalls of Bard PowerPort devices for issues including device design problems, catheter defects, and ECG signal loss during placement.
FDA MAUDE database contains over 5,333 adverse event reports for Bard PowerPort devices, including fractures, migrations, infections, and material separation.
10 The New Jersey State Court Track (MCL)
Beyond the federal MDL, Bard port catheter cases are also consolidated in New Jersey state court. The New Jersey Multicounty Litigation (MCL) is centralized in Bergen County before Judge Gregg Padovano and was designated on October 15, 2024. It runs on its own schedule and its own rulings, separate from the Arizona MDL.
The state track can matter for claimants whose cases are filed in or belong in New Jersey, and firms weighing inventory should decide explicitly whether they want the state track in addition to the federal MDL, because the two move independently. We have not been able to verify a current case count for the New Jersey MCL from a primary source, so we do not state one.
11 Filing Velocity: One of the Fastest-Growing Device MDLs
The docket is growing fast. Pending federal actions rose by 205 between the October and November 2026 reports, from 4,140 to 4,345. That follows a 406-case jump in the October report, which likely reflected about two months of filings because the September report repeated August's figures exactly, so the docket is adding roughly 200 cases a month (see the case-growth chart above). That pace makes MDL-3081 one of the fastest-growing device MDLs of its size on the federal docket.
Filing velocity is not the same as case strength. The first and third bellwethers ended in defense verdicts on the decided claims, so rapid growth should be read as a measure of how many claimants are coming forward, not as a prediction of outcome. It is, however, the reason this litigation sits at the center of device-MDL attention in 2026, and it is why the Divelbliss fracture verdict in September, the first plaintiff verdict in the MDL, is so significant.
12 The Legal Claims and What Has Been Decided
The complaints plead several distinct theories, and the Cook, Divelbliss and Lattanzio verdicts are the first real data points on how they fare in front of a jury. Understanding which claim is which explains why each new bellwether matters.
Design defect is the central claim: that the catheter is unreasonably dangerous as designed because the barium sulfate is alleged to degrade and weaken the material. This is the claim the Cook jury hung on. In the second bellwether, Divelbliss, a fracture case, the jury found for the plaintiff on design defect on September 4, 2026, the first time a jury in this MDL decided the claim. Failure to warn and failure to instruct allege that Bard did not adequately warn physicians of the risks or provide adequate directions for use; the Cook jury found for Bard on both, though the Divelbliss jury found failure to warn for the plaintiff. Consumer fraud and unlawful trade practices allege deceptive marketing; the Cook jury also found for Bard there. The third jury, in the Lattanzio infection case, returned a defense verdict, Law.com reported on October 30, 2026; how it decided each claim has not been made public.
Two procedural points frame all of this. First, plaintiffs cleared the general-causation gate earlier in the litigation, meaning the court accepted that the alleged mechanism can, in general, cause the injuries claimed; the fights now are over specific cases and specific defect theories. Second, Judge Campbell denied nearly all of Bard's summary-judgment motion on March 5, 2026, so the claims survived to be decided on their merits rather than being thrown out beforehand. The open question the bellwethers are answering is whether a jury will find the design itself defective, and the injury type in front of them (infection, fracture, or thrombosis) may change the answer.
13 Do You Qualify for Compensation?
You may be eligible to file a claim if you meet these criteria:
Eligibility Requirements
- Had a Bard PowerPort implanted — Including any PowerPort, PowerPort isp, PowerPort MRI, PowerPort ClearVUE, or similar Bard port catheter
- Experienced a qualifying complication — Catheter fracture, fragment migration, bloodstream infection/sepsis, deep vein thrombosis, or required surgical removal
- Can document the device and injury — Medical records showing device implantation and subsequent complications
- Within the statute of limitations for your state, which varies and is often measured from when the injury was discovered rather than the implant date. Confirm the deadline that applies to you with an attorney rather than relying on a general figure.
Free, confidential case review. No obligation.
14 Frequently Asked Questions
What is a PowerPort and who uses one?
What is the alleged defect?
What are the three catheter materials in the bellwether cases?
What injuries are alleged in the lawsuits?
Who are the defendants?
When will trials begin?
What happened in the first bellwether trial?
What is the Divelbliss trial and why does it matter?
Why was the bellwether slate reduced from six cases to five?
Have there been any settlements?
Is there a New Jersey state court case?
Is there a related port catheter MDL?
What is the statute of limitations for a PowerPort claim?
Free, confidential review. It takes about two minutes.
Sources & References
9 official sources cited• FDA 510(k) Premarket Notification Database — Device clearance records (14 PowerPort clearances 2006-2025)
• FDA MAUDE Database — 5,333+ adverse event reports for Bard PowerPort
• FDA Medical Device Recalls Database — 25 Class II recalls (2018-2021)
• Braun U, et al. "Mechanic and surface properties of central-venous port catheters after removal." J Mech Behav Biomed Mater. 2016 (PMID: 27552159)
• Kondo et al. (2020), CVIR Endovasc — Catheter fracture incidence rates (1.1%-5.0%)
• CDC, "CLABSI Basics" — Central line catheter information (Updated June 2025)
• Judicial Panel on Multidistrict Litigation (JPML) — MDL statistics and docket reports
• SEC EDGAR Database — Becton Dickinson/C.R. Bard acquisition filings (December 2017)
• U.S. District Court, District of Arizona — MDL-3081 case management orders
Had a Bard PowerPort and a serious complication?
If you had a Bard PowerPort implanted and experienced a catheter fracture, fragment migration, a bloodstream infection, sepsis, or a blood clot, you may be eligible to file a claim. Filing deadlines vary by state, so it is worth checking promptly.
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.